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Aims The choice of resynchronization therapy between with (CRT-D) and without (CRT-P) a defibrillator remains a con-
tentious issue. Cause-of-death analysis among CRT-P, compared with CRT-D, patients could help evaluate the extent
to which CRT-P patients would have additionally benefited from a defibrillator in a daily clinical practice.
Methods
and results
A total of 1705 consecutive patients implanted with a CRT (CRT-P: 535 and CRT-D: 1170) between 2008 and 2010
were enrolled in CeRtiTuDe, a multicentric prospective follow-up cohort study, with specific adjudication for causes of
death at 2 years. Patients with CRT-P compared with CRT-D were older (P, 0.0001), less often male (P, 0.0001),
more symptomatic (P ¼ 0.0005), with less coronary artery disease (P ¼ 0.003), wider QRS (P ¼ 0.002), more atrial
fibrillation (P, 0.0001), and more co-morbidities (P ¼ 0.04). At 2-year follow-up, the annual overall mortality rate
was 83.80 [95% confidence interval (CI) 73.41–94.19] per 1000 person-years. The crude mortality rate among
CRT-P patients was double compared with CRT-D (relative risk 2.01, 95% CI 1.56–2.58). In a Cox proportional ha-
zards regression analysis, CRT-P remained associated with increased mortality (hazard ratio 1.54, 95% CI 1.07–2.21,
P ¼ 0.0209), although other potential confounders may persist. By cause-of-death analysis, 95% of the excess mortality
among CRT-P subjects was related to an increase in non-sudden death.
Conclusion When compared with CRT-D patients, excess mortality in CRT-P recipients was mainly due to non-sudden death. Our
findings suggest that CRT-P patients, as currently selected in routine clinical practice, would not potentially benefit with
the addition of a defibrillator.
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Patients with congestive heart failure (HF) are at high risk of dying
from its progression as well from sudden cardiac death related to
ventricular tachyarrhythmia.1 Over the last decade, cardiac resyn-
chronization therapy (CRT) and implantable cardioverter defibril-
lators (ICDs) have markedly improved the prognosis of HF
patients, with prolongation of survival over and above that con-
ferred by medical therapy alone.2 – 5 It has been well established
in trials that in patients with severe left ventricular (LV) systolic
dysfunction, New York Heart Association (NYHA) class III/IV
symptoms, and wide QRS, CRT improves symptoms/quality of
life and also reduces mortality.3,6 Additionally, more recent trials
have shown beneficial reverse LV remodelling even in patients
with milder symptoms.5,7 – 11 This has resulted in a class I recom-
mendation for CRT in appropriately selected candidates in guide-
lines framed on both sides of the Atlantic.12,13
Since most patients who are candidates for CRT will have a LV
ejection fraction (EF) of ≤35%, this ‘automatically’ makes them can-
didates for an ICD as well by the current guidelines, which makes
the assumption that there is universally significant excess mortality
due to sudden cardiac death (SCD) among CRT-P patients who can
therefore definitively benefit from the added defibrillator.13 How-
ever, concrete evidence for such a premise in a contemporary
CRT-P population is lacking and in any population of this kind;
competing risks for mortality need to be carefully considered.
A few studies have attempted to directly compare outcomes be-
tween CRT-P vs. CRT-D subjects.14,15 Furthermore, such outcome
comparisons based on observational studies have methodological
limitations and may be biased. Current guidelines do not make
firm recommendations in terms of the choice between CRT-P vs.
CRT-D, leaving room for physician discretion. This has resulted in
wide variation in the rates of implantation worldwide. For instance,
the proportion of CRT implantations, which are CRT-D, reaches
.90% in most practices in the USA,16 whereas it is relatively lesser
across Europe.17 The use of CRT-D or CRT-P in clinical practice is
an important question with significant implications in terms of
costs,18 as well as device-related complications.19,20
In this context, a better understanding of the relative contribu-
tion of SCD as opposed to other competing causes of mortality in
the CRT population can be very informative. A cause-of-death
analysis among CRT-P vs. CRT-D patients, may represent a novel
approach to this problem. Using a large, multicentre study with
prospective follow-up, we evaluated the characteristics of
CRT-P vs. CRT-D patients in a real-world scenario and analysed
to what extent CRT-P subjects, as currently chosen in clinical
practice, would have potentially additionally benefited from the
presence of a back-up defibrillator.
Methods
Setting and design of the study
CeRtiTuDe, a 2-year, prospective, multicentre registry launched in Janu-
ary 2008 and held under the direction of the Working Group on Pacing
and Arrhythmias of the French Society of Cardiology, was funded and
coordinated by the French Society of Cardiology. Its primary objective
was to define the baseline characteristics and clinical outcomes of
French patients who undergo implantation of CRT systems. An analysis
of the precise causes of death was planned at 2 years after device
implantation.
The 41 medical centres participating in the study (Appendix) enrolled
consecutive patients who, between 1 January 2008 and 31 December
2010, had undergone CRT device implantations. The criteria for CRT
implantation were as per the 2007 guidelines of the European Society
of Cardiology and European Heart Rhythm Association, updated
in 2010. However, all CRT recipients were enrolled, in order for the
registry to reflect ‘real-world’ medical practice. Each patient was then
enrolled in a specific follow-up programme with clinical, ECG, echocar-
diographic, and device interrogation data collected every 6 months over
the following 2 years (up to 1 January 2013).
The study was conducted in accordance with Good Clinical Practice,
French Law, and the French data protection law. The protocol was re-
viewed by the Committee for the Protection of Human Subjects in Bio-
medical Research (CCTIRS #08-522) and the data file was reported to,
and authorized by, the Commission Nationale Informatique et des Lib-
erte´s (French Data Protection Committee, CNIL #909048).
Baseline characteristics at implant
Individual patient data were collected, using an electronic case report
form created by the Scientific Committee to record, at each participat-
ing medical centre, the demographic and baseline clinical characteristics,
and the implantation procedures and techniques. These data were regu-
larly transferred (every 3 months) via an internet-based system to a cen-
tral database created at the data management centre of the French
Society of Cardiology in collaboration with the Paris Cardiovascular Re-
search Center, European Georges Pompidou Hospital, Paris (INSERM
Unit 970).
All variables recorded before device implantation were defined and
classified using standard clinical terminology, including gender, age
(stratified as ,60, 60–74, and ≥75 years), and underlying heart disease
(ischaemic vs. non-ischaemic). Renal clearance was estimated using the
Cockroft and Gault’s formula, and defined as severe renal insufficiency if
,30 mL/min/1.73 m2, and QRS duration was classified as ≤120, 121–
149, and ≥150 ms. Left ventricular ejection fraction was measured on
transthoracic echocardiograms, using Simpson’s method, and recorded
as a continuous variable and also stratified as ≤20, 21–35, and .35%.
A history of atrial fibrillation (AF) was based on medical records, and
classified as paroxysmal or permanent. In addition to AF and renal fail-
ure, other co-morbidities were systematically recorded, including can-
cer, chronic obstructive pulmonary disease, liver disease, diabetes
mellitus, and cerebral vascular disease.
Device implant, hospital discharge,
and follow-up
The type of CRT (CRT-P or CRT-D) implanted was recorded without
the manufacturer’s information. The complications recorded included
infections, changes in capture threshold, lead dislodgement, haema-
tomas, HF, fever, arrhythmias, pneumothorax, phrenic nerve stimula-
tion, and death. Finally, drug regimens prescribed at the time of
hospital discharge including beta-adrenergic blockers, anti-arrhythmics,
digoxin, calcium antagonists, angiotensin-converting enzyme inhibitors
or angiotensin II receptor blockers, mineralocorticoid receptor antago-
nists, diuretics, and anticoagulants were recorded. Device programming
was left to the discretion of the investigators at each centre, with the
guiding principle being achievement of maximal biventricular pacing.
All patients were followed at 6-month intervals for 2 years by the im-
planting centre till the close of study on 1 January 2013. At each follow-
up, the patients underwent clinical examination, ECG, transthoracic
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echocardiogram, and device interrogation. In addition, information on
any intercurrent events (such as hospitalization) was also recorded in
the file. The above data were systematically gathered at each follow-up
visit from the date of device implantation to study closure or death or
heart transplantation.
Vital status, specific causes of death,
and adjudication process
The investigators at each enrolling centre recorded major clinical
events, using a standardized form, and a Clinical Events Committee
verified their accuracy by contacting the attending physicians or the pa-
tients as required, on a yearly basis, focusing on the vital status and on
the specific modes and causes of death and on major clinical events or
interventions during follow-up, including changes in drug regimens, as
well as interim hospitalizations. Sources to ascertain the vital status
also included registries of the patients’ birthplaces, the French National
Institute of Health and Medical Research (INSERM Ce´piDc Unit—
Le Kremlin-Biceˆtre, France), and the French National Institute of Statis-
tics and Economical Studies.
The cause-of-death were classified as sudden if the patient (i) died
suddenly and unexpectedly within 1 h of symptoms in the absence of
progressive cardiac deterioration, (ii) died unexpectedly in sleep, or
(iii) died unexpectedly within 24 h after last being seen alive and in
the usual state of health. Other cardiovascular deaths included myocar-
dial infarction, HF, acute aortic syndrome, stroke, and pulmonary em-
bolism. Fatal arrhythmias associated with end-stage HF were classified
as non-sudden cardiovascular deaths. Deaths attributable to causes,
such as cancer, infectious disease, or renal or respiratory failure, were
classified as non-cardiovascular. When inadequate or no data were
available, the cause of death was classified as unknown or unidentifiable.
We used multiple sources to assess and finally adjudicate the cause of
death, which included medical data obtained by the regional investiga-
tors, pathology report, Emergency Medical Services report, as well as
data from the French Center on Medical Causes of Death (INSERM
Ce´piDc unit), which is able to provide the causes of death occurring
in France.
Statistical analysis
This report was prepared in compliance with the STROBE checklist
for observational studies.21 Continuous variables are presented as
mean+ standard deviation and categorical variables are presented
as numbers and percentages. Comparisons between groups (patients
with CRT-P vs. patients with CRT-D) were made, using the x2 or
Fisher’s exact tests for discrete variables and with unpaired t-tests,
Wilcoxon signed-rank tests, or one-way analysis of variance for continu-
ous variables. Factors associated with the implantation of CRT-P were
identified, using a multiple variable, stepwise, logistic regression analysis.
Kaplan–Meier curves were constructed to estimate the 2-year sur-
vival, and CRT-P and CRT-D groups were compared using the log-rank
test. For the cause-specific mortality, we used a competing risk analysis
and estimated the cumulative incidence function. We then used Gray
tests to assess the difference between the CRT-P and CRT-D groups.22
A Cox proportional hazards regression analysis was used to identify
variables independently associated with overall mortality. The propor-
tional hazard assumptions were tested. The crude associations between
mortality and different variables (listed in Table 1) were first quantified
by univariate Cox regression. All covariates that reached a significance
level of P, 15% were then included in an initial multivariate regres-
sion model. A stepwise selection was applied to obtain a final model
that included covariates with P, 5%. Given the observational design
of the study and minimization of indication bias for device
implantation, propensity score analyses were conducted. We esti-
mated the propensity score of receiving a CRT-P therapy by fitting a
logistic regression model using age, sex, AF, LVEF, aetiology of HF,
NYHA, and beta-adrenergic blockers as covariates. We then matched
patients who received CRT-D therapy with those who received
CRT-P in an 1 : 1 ratio using a greedy matching algorithm with a max-
imum allowable difference of 0.05 (see Supplementary material online,
Table S1 and Figure S1). Patients who could not be matched using these
criteria were removed from the analysis. Then, the association be-
tween device type and mortality was repeated after propensity score
matching (462 patients). All data were analysed at INSERM, Unit 970,
Cardiovascular Epidemiology and Sudden Death, Paris, using SAS ver-
sion 9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
Baseline characteristics and device
implantation
Overall, a total of 1705 consecutive patients were enrolled in the
study and received CRT devices. The mean age of the overall popu-
lation was 68.8+11.1 years, 33% were .75 years of age, and 77%
were men. Nearly 20% had been hospitalized for decompensated
HF within the previous 6 months. The heart disease was ischaemic
in 47% of patients and related to non-ischaemic dilated cardiomyop-
athy in 53%. Overall, 29% of patients presented with a LVEF of
≤20% at the time of implantation.
A CRT-D was implanted in 1170 patients (69%). Overall, 13% of
the CRT-D group was implanted in the secondary prevention, fol-
lowing symptomatic ventricular tachycardia or sudden cardiac ar-
rest. Patients with CRT-P compared with CRT-D were older
(75.9 vs. 65.6 years, P, 0.0001), less often male (69.5 vs. 80.8%,
P, 0.0001), more symptomatic (proportion of NYHA class III/IV,
87.9 vs. 80.8%, P ¼ 0.0005), with less coronary artery disease
(40.7 vs. 49.3%, P ¼ 0.003), wider QRS (160.8 vs. 154.9 ms,
P ¼ 0.002), more AF (38.7 vs. 22.1%, P, 0.0001), and more co-
morbidities (≥2 comorbidities, 16.9 vs. 12.9%, P ¼ 0.04; Table 1).
Independent variables associated with CRT-P (vs. CRT-D) implant-
ation are depicted in Table 2.
Fatal periprocedural complications occurred in one patient, and
death occurred before hospital discharge in five others (0.3%),
due to severe cardiogenic shock. Overall, significant perioperative
complications occurred in 133 subjects (7.8%) without significant
difference between CRT-D and CRT-P (8.9 vs. 6.7%, P ¼ 0.20).
Pulse generator pocket haematoma (2.5%), lead dislodgment
(1.6%), and phrenic nerve stimulation (1.6%) were the most fre-
quent complications, and the need for new intervention during
the same hospital stay was observed in 40 patients (2.3%).
Follow-up, overall mortality, and specific
causes of death
The 1705 consecutive patients enrolled in the study were followed
for a mean of 665.6+ 173.8 days (1.0–730.5 days). At 2-year
follow-up (completed in 94.5% of subjects), 267 patients died, giving
an overall annual mortality rate of 83.8% (95% CI 73.4–94.2) per
1000 person-years, with a higher rate among CRT-P, compared
with CRT-D, patients [130.8 vs. 65.1 per 1000 year, respectively,
relative risk (RR) 2.01, 95% CI 1.56–2.58, P, 0.0001; Figure 1A].
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The incidence of SCD was not statistically higher in the CRT-P
group compared with CRT-D (RR 1.57, 95% CI 0.71–3.46, P ¼
0.42) (Figure 1B). The rate of hospitalization for HF was not different
between the CRT-D vs. CRT-P groups (19.6 vs. 22.0%, P ¼ 0.28).
After considering potential confounding factors in a Cox pro-
portional hazards regression analysis, CRT-P remained associated
with increased mortality [hazard ratio (HR) 1.54, 95% CI 1.07–
2.21, P ¼ 0.0209], as well as the presence of co-morbidities (HR
1.98, 95% CI 1.34–2.92, P ¼ 0.0006) and functional NYHA class
IV (HR 1.85, 95% CI 1.10–3.11, P ¼ 0.0207). Using the propensity-
matched cohort, CRT-P was associated with increased mortality
(RR 2.0, 95% CI 1.22–3.28, P ¼ 0.01). Cardiac resynchronization
therapy without defibrillator was not associated with a higher
incidence of SCD (RR 1.21, 95% CI 0.45–3.29, P ¼ 0.70). Forest
plots showing hazard ratios of CRT-P vs. CRT-D for mortality by dif-
ferent subgroups were represented in Figure 2.
However, when considering the specific cause-of-death analysis
(Table 3), the increase in mortality among CRT-P patients was not
related to that in SCD, though SCD incidence was higher in the
CRT-P group: 11.8 per 1000 among CRT-P vs. 7.5 per 1000 among
CRT-D recipients (P ¼ 0.26). The main reasons for the almost
twice-higher risk of death in the CRT-P group were an increase in
non-SCD cardiovascular mortality, mainly comprising progressive
HF (RR 2.27, 95% CI 1.62–3.18) as well as other cardiovascular
mortality (RR 4.40, 95% CI 1.29–15.03). Overall, 95% of the excess
mortality among CRT-P recipients was not related to SCD.
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Table 1 Characteristics of the entire registry sample and of the CRT-P vs. CRT-D recipients
Total (N5 1705) CRT-D (N 5 1170) CRT-P (N 5 535) P-value
Age (years) 68.8+11.1 65.6+10.4 75.9+9.0 ,0.0001
Men 1317 (77.2) 945 (80.8) 372 (69.5) ,0.0001
Heart disease
Ischaemic 724 (47.0) 556 (49.3) 168 (40.7) 0.0026
Non-ischaemic 816 (53.0) 571 (50.7) 245 (59.3)
QRS duration
Mean (ms) 157.7+27.1 155.0+26.2 160.8+29.0 0.0018
Left ventricular ejection fraction
Median, % 25.5 (10.0) 25.5 (10.0) 25.5 (10.0) 0.084
≤20% 484 (29.3) 333 (29.2) 151 (29.6) ,0.0001
21–35% 1078 (65.3) 764 (67.1) 314 (61.5)
.35% 88 (5.3) 42 (3.7) 46 (9.0)
New York Heart Association functional class
I 16 (1.0) 14 (1.3) 2 (0.4) ,0.0001
II 250 (16.0) 194 (18.0) 56 (11.7)
III 1188 (76.2) 824 (76.2) 364 (76.0)
IV 106 (6.8) 49 (4.5) 57 (11.9)
History of:
Atrial fibrillation 445 (27.3) 248 (22.1) 197 (38.7) ,0.0001
Renal insufficiency 211 (14.4) 138 (13.0) 73 (18.2) 0.0128
COPD 264 (18.1) 198 (18.7) 66 (16.4) 0.3120
Cancer 122 (8.4) 88 (8.3) 34 (8.5) 0.9272
Miscellaneous disorders 266 (18.2) 174 (16.4) 92 (22.9) 0.0043
Drug therapy at the time of implantation
Diuretics 1045 (66.2) 752 (69.2) 293 (59.6) 0.0002
ACE inhibitors/ARB 1057 (66.9) 792 (72.9) 265 (53.9) ,0.0001
MRA 404 (25.6) 331 (30.5) 73 (14.8) ,0.0001
Beta-adrenergic blockers 945 (59.9) 732 (67.3) 213 (43.3) ,0.0001
Oral anticoagulant agent 658 (41.7) 438 (40.3) 220 (44.7) 0.0989
Antiplatelet agents 693 (43.9) 512 (47.1) 181 (36.8) 0.0001
Values are means+ SD, median (IQR), or numbers (%) of observations.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; MRA, mineralocorticoid receptor antagonist; CRT-D:
cardiac resynchronization therapy with defibrillator; CRT-P: cardiac resynchronization therapy without defibrillator.
E. Marijon et al.2770







To the best of our knowledge, our study provides the first
cause-of-death analysis comparing CRT-P with CRT-D patients in
a real-world population. We demonstrate that CRT-P patients, as
chosen in routine clinical practice, were older, more likely to be fe-
male, with less ischaemic heart disease, more advanced HF, and
greater co-morbidity burden compared with CRT-D patients.
These characteristics of the CRT-P patients are in agreement with
previous reports.14,19 At 2 years, the overall mortality in the
CRT-P group was greater than that in the CRT-D group. However,
importantly, this difference in mortality was mostly accounted for by
an increase in non-SCD. Since SCD did not significantly contribute
to the excess mortality in the CRT-P group, it suggests that the pres-
ence of a back-up defibrillator would probably not have been bene-
ficial in terms of improving survival for these patients. The rates of
HF hospitalization were greater in the CRT-P group, which is in line
with the greater HF mortality in this group. This is likely related to a
sicker population with more co-morbidity, older age, and potentially
more severe HF and serves to highlight that progressive HF rather
than SCD may be the main driver of morbidity as well as mortality in
the CRT-P population. These results from a large, prospective co-
hort with robust cause-of-death adjudication need careful consider-
ation in the context of the current controversy in the selection of
CRT-P vs. CRT-D. Our study is not intended as a direct comparison
of outcomes between CRT-D and CRT-P, and subgroup analyses
should be interpreted with caution. While direct comparisons in ob-
servational studies may reveal differences in death rates, knowledge
of what makes up this difference takes our understanding an import-
ant step further. Cause-of-death analysis, while being technically
challenging to perform in a large population, represents an innova-
tive, alternate approach to this problem. It also helps bring to the
forefront the issue of competing risks for mortality in any population
of this nature.
With the exception of patients with AF, where the evidence-base
is admittedly weaker,20 CRT represents an important therapeutic
option for a growing segment of the HF population. Though the
guidelines presently do not make definitive recommendations for
CRT-D vs. CRT-P, in practice, many physicians may feel compelled
to use CRT-D, as a defibrillator is considered ‘necessary’ in the pres-
ence of low LVEF. The effect of this choice may be even greater in
light of the fact that many centres are exploring broader indications
for CRT in patients with milder symptoms and narrow QRS.23 This
has important economic implications in that the incremental cost of
CRT-D over CRT-P is significantly greater when compared with the
cost over optimal medical therapy and this difference is even steeper
in the older age group.24 The addition of a defibrillator lead can also
contribute to additional adverse events and need for repeat proce-
dures.25 Thus, there is a fairly urgent need for more data such as
from the present study to tease out the putative benefits of an
added defibrillator over CRT-P,25 and to better define optimal
criteria to select CRT-P or CRT-D. Since the CRT-P group had a
greater proportion of non-ischaemic cardiomyopathy where the
benefit from primary preventive ICD is lower, this could influence
results as well.6 In the absence of proven superiority by trials and
the small survival benefit, the 2013 European Society of Cardiology
Task Force was of the opinion that no strict recommendations can
be made, and has preferred to merely offer guidance regarding the
selection of patients for CRT-D or CRT-P,13 based on overall clin-
ical condition, device-related complications, and cost; factors fa-
vouring CRT-P being advanced HF, co-morbidities, including frailty
and cachexia. In contrast, factors favouring CRT-D implantation are
life expectancy .1 year, stable HF, moderate functional status, is-
chaemic heart disease, and lack of comorbidities being in favour of
CRT-D implantation, and the French practice appears to be in
agreement with this.
The only randomized trial to have CRT-P as well as CRT-D
arms—the COMPANION trial did not show a significant benefit
of CRT-D over CRT-P for the primary endpoint.6 However, the
study was not powered to compare these two treatments. Non-
randomized studies, which have compared outcomes for these
two modalities, have yielded conflicting results. Using registry-based
data, Morani et al.14 showed that among patients with an European
Society of Cardiology Class IA indication for CRT, CRT-D was asso-
ciated with better survival than CRT-P. Similar findings were re-
ported from a US-based registry, which concluded that ‘CRT-D
should be recommended to most congestive HF patients with indi-
cations for biventricular pacing’.27 However, recent experience with
reasonable numbers of patients emphasized the higher risk of mor-
tality among CRT-P patients compared with CRT-D, indicating that
long-term benefit of an additional defibrillator may be restricted to a
selected subgroup.15,19 Furthermore, logistic regression models
which are relied on in comparative studies to draw conclusions,
may not adequately overcome the limitations in comparing hetero-
geneous groups.28 A Bayesian network meta-analysis in 2007 con-
cluded that evidence from randomized trials is insufficient to
prove the superiority of CRT-D over CRT-P.29
Whether CRT-P by itself reduces risk of arrhythmia is still a mat-
ter of some debate. Long-term data from CARE-HF show reduction
in SCD rates by CRT.30 A mechanistic link is supported by the fact
that SCD is reduced in subjects with systolic HF and ventricular dys-
synchrony.31 Recent analysis from the MADIT-CRT trial showed
that risk of ventricular arrhythmias was significantly reduced in
CRT patients with normalization of LVEF. Importantly, risk of in-
appropriate ICD therapy was unchanged, suggesting that these
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Independent variables associated with CRT-P
(vs. CRT-D) implantation
Variables OR 95% CI P-value
Age 1.17 1.14–1.19 ,0.0001




Atrial fibrillation 1.58 1.14–2.20 0.0062
LVEF ,25% 1.05 1.02–1.07 0.0001
NYHA IV 2.82 1.61–4.92 0.0003
No beta-adrenergic blockers 2.40 1.76–3.26 ,0.0001
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association;
CRT-D: cardiac resynchronization therapy with defibrillator; CRT-P: cardiac
resynchronization therapy without defibrillator.
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patients may be better served by a downgrade to CRT-P at device
change.32 Similarly, another study showed that based on LVEF im-
provement, up to one-third of CRT-D patients no longer had an on-
going indication for ICD at the time of battery change and the rate of
device therapy in this group was very low.33 By inducing favourable
remodelling of the LV, CRT may reduce the substrate for ventricular
arrhythmias. Some patients experience rapid reverse remodelling
(‘super responders’), with major improvement in EF so that they
are no longer ICD candidates. Data suggest that such patients
have excellent long-term prognosis.34,35 In anticipation of rapid im-
provement of LVEF, it would seem logical to provide temporary
protection against SCD such as using a life vest rather than implant-
ing a defibrillator. However, although predictors of super response
have been proposed,36,37 it is still difficult to identify such super re-
sponders with a high degree of confidence; thus, more work may be
needed in this regard. The rationale for an anti-arrhythmic effect of
CRT is also tempered to some extent by concerns over the
pro-arrhythmic effects of LV pacing.38,39 Prospective follow-up of
patients with CRT-P has shown that the incidence was overall rela-
tively low, and that sudden cardiac death events were likely to be
preceded by recorded sustained ventricular arrhythmias, emphasiz-
ing the importance of regular CRT-P device memory interrogation,
as well as the potential benefit of remote monitoring in these pa-
tients, for possible urgent upgrading to CRT-D.40 The possibility
of accurate and continuous surveillance to detect life-threatening
arrhythmias, with upgrading of CRT-P patients to CRT-D only after
Figure 1 Overall mortality incidence over time according to CRT-P and CRT-D groups. (A) Overall mortality and (B) sudden cardiac death.
CRT-D: cardiac resynchronization therapy with defibrillator; CRT-P: cardiac resynchronization therapy without defibrillator.
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such objective documentation during follow-up, might represent a
safe and cost-effective alternative to the practice of universal
CRT-D implantation in all CRT candidates.
Our results should not be interpreted as a general lack of benefit
from CRT-D vs. CRT-P or vice versa. Rather, we demonstrate that
given currently selected CRT-P patients in the French population,
addition of a defibrillator may not significantly add to survival. At
least in a subset of the ‘CRT eligible’ HF population, competing risks
of non-sudden death may diminish the incremental value of adding a
defibrillator to CRT; therefore, all patients eligible for CRT cannot
be ‘automatically’ considered as requiring a CRT-D. Thus, in a
broader context, the requirement for CRT-D in similar populations
needs careful consideration of the putative risks and benefits.
Relative strengths of the present study include the fact that
it is prospective, multicentric with dedicated cause-of-death adjudi-
cation. However, we acknowledge some limitations. First, the study
was non-randomized and therefore, selection bias may have influ-
enced results. The clinical decision concerning device type may af-
fect subsequent management as well lead to variations in clinical
care. On the other hand, randomized trials, while being a rigorous
design, have rigid selection criteria, which often do not reflect real-
world scenarios. Though the results need to be interpreted with
caution in view of potential confounding, it reflects actual clinical
practice. Secondly, follow-up was censured at 2 years, which can in-
fluence results as device utilization is a function of time; however,
there were adequate events during follow-up to draw reasonable
conclusions. Thirdly, information on QRS morphology was unavail-
able and the extent of LBBB in the two groups may have influenced
CRT outcomes. Finally, although our study suggests that mortality in
this real-world CRT-P population may not be improved by upgrade
to CRT-D, it does not address the question of whether, in the popu-
lation implanted with a CRT-D device, CRT-P would perform just as
well. Thus, this study was not intended to answer the question of
whether CRT-P is comparable with CRT-D overall, but rather pro-
vides a real-world assessment of cause of death in a contemporary
CRT-P vs. CRT-D population, which we believe can more meaning-
fully inform clinical practice. It should be borne in mind that these
outcomes mainly pertain to a HF population with broad QRS.
Conclusion
In this prospective, multicentre cohort study, CRT-P patients were
older, with more advanced HF, and co-morbidities when compared
with CRT-D recipients. At 2-year follow-up, CRT-P patients had
2-fold higher mortality than CRT-D. By cause-of-death analysis,
the excess mortality among CRT-P subjects was almost entirely
related to non-SCD. Our results indicate that CRT-P patients, as
currently selected in routine clinical practice, would potentially
not benefit from addition of a defibrillator, emphasizing that
there is still considerable room for CRT-P in the present day HF
treatment.
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Table 3 Incidence of specific causes of death among CRT-P and CRT-D recipients
Incidences (per 1000 patient-years) CRT-P (N 5 535) CRT-D (N 5 1170) Unadjusted risk ratio (95% CI)
Total mortality 130.8 65.1 2.01 (1.56–2.58)
Cardiovascular
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CRT-D: cardiac resynchronization therapy with defibrillator; CRT-P: cardiac resynchronization therapy without defibrillator.
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